文献速递肺外科心外重症与机械循环支持

单中心四十年心肺联合移植二百七十一例进展

Four decades of progress in heart-lung transplantation: Two hundred seventy-one cases at a single institution.
PubMed 文献 · J Thorac Cardiovasc Surg · 2024-02-05

该单中心研究分析了1981至2022年间271例心肺联合移植受者的生存情况,按 pioneering era(1981-2000年,n=155)与 modern era(2001-2022年,n=116)分组,经基数匹配后现代组30天、1年及10年生存率均显著优于开创组,结论认为长期生存可随机构经验积累而实现。

要点

  • 现代组受者年龄更大(42岁 vs 34岁,P<.001),等待时间更短(78天 vs 234天,P<.001)。
  • 匹配分析显示现代组30天生存率97% vs 84%(P=.005),1年89% vs 77%(P=.041),10年53% vs 26%(P=.012)。
  • 女性供体在现代组更常见(59% vs 39%,P=.002)。

核心结论

  • 心肺联合移植的长期生存可随机构经验积累而实现,并可能在未来数十年继续改善。
  • 机械循环支持进展、维持性免疫抑制改善以及对原发性移植物功能障碍和急性排斥等急性并发症的早期识别与管理,显著改善了本机构当代心肺联合移植受者的预后。

研究设计与样本

  • 单中心回顾性分析,数据来自科室数据库及器官共享联合网络。
  • 排除18岁以下、再次心肺联合移植或三器官系统移植受者,最终纳入271例。
  • 开创期定义为1981至2000年间移植(n=155),现代期定义为2001至2022年间移植(n=116)。
  • 生存分析采用基于供受者年龄、供受者性别、缺血时间及性别匹配的基数匹配。

主要发现

  • 现代期受者年龄大于开创期(42岁 vs 34岁,P<.001),等待名单时间短于开创期(78天 vs 234天,P<.001)。
  • 现代期女性供体比例高于开创期(59% vs 39%,P=.002)。
  • 匹配生存分析中,现代期30天生存率97% vs 开创期84%(P=.005),1年生存率89% vs 77%(P=.041),10年生存率53% vs 26%(P=.012),均为现代期显著改善。

关键数值与推荐

  • 现代期受者年龄42岁 vs 开创期34岁(P<.001)。
  • 现代期等待名单时间78天 vs 开创期234天(P<.001)。
  • 现代期女性供体59% vs 开创期39%(P=.002)。
  • 匹配后现代期30天生存率97% vs 开创期84%(P=.005)。
  • 匹配后现代期1年生存率89% vs 开创期77%(P=.041);10年生存率53% vs 开创期26%(P=.012)。

临床怎么用

  • 原文结论未据此给出具体临床推荐,仅指出长期生存可随机构经验积累而实现,并可能在未来数十年继续改善。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study is to evaluate survival for combined heart-lung transplant (HLTx) recipients across 4 decades at a single institution. We aim to summarize our contemporary practice based on more than 271 HLTx procedures over 40 years. METHODS: Data were collected from a departmental database and the United Network for Organ Sharing. Recipients younger than age 18 years, those undergoing redo HLTx, or triple-organ system transplantation were excluded, leaving 271 patients for analysis. The pioneering era was defined by date of transplant between 1981 and 2000 (n = 155), and the modern era between 2001 and 2022 (n = 116). Survival analysis was performed using cardinality matching of populations based on donor and recipient age, donor and recipient sex, ischemic time, and sex matching. RESULTS: Between 1981 and 2022, 271 HLTx were performed at a single institution. Recipients in the modern era were older (age 42 vs 34 y; P < .001) and had shorter waitlist times (78 vs 234 days; P < .001). Allografts from female donors were more common in the modern era (59% vs 39%; P = .002). In the matched survival analysis, 30-day survival (97% vs 84%; P = .005), 1-year survival (89% vs 77%; P = .041), and 10-year survival (53% vs 26%; P = .012) significantly improved in the modern era relative to the pioneering era, respectively. CONCLUSIONS: Long-term survival in HLTx is achievable with institutional experience and may continue to improve in the coming decades. Advances in mechanical circulatory support, improved maintenance immunosuppression, and early recognition and management of acute complications such as primary graft dysfunction and acute rejection have dramatically improved the prognosis for recipients of HLTx in our contemporary institutional experience.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Elde S, Baccouche BM, Mullis DM, et al. Four decades of progress in heart-lung transplantation: Two hundred seventy-one cases at a single institution. J Thorac Cardiovasc Surg. 2024. PMID: 38320627. doi:10.1016/j.jtcvs.2024.01.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。